MADRIGAL PHARMACEUTICALS,INC. (NASDAQ:MDGL) Files An 8-K Results of Operations and Financial Condition

ME Staff 8-k
-
0

MADRIGAL PHARMACEUTICALS,INC. (NASDAQ:MDGL) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition.

On May8, 2018 Madrigal Pharmaceuticals,Inc. (the “Company”) issued a press release announcing the Company’s financial results for its first fiscal quarter ended March31, 2018. A copy of the press release is furnished herewith as Exhibit99.1 to this Current Report on Form8-K and is incorporated herein by reference.

The information in this Current Report on Form8-K and the accompanying Exhibit99.1 shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing, unless expressly incorporated by reference in such filing.

Item 2.02 Financial Statements and Exhibits.

(d)Exhibits

Exhibit Number

Description

99.1

Press Release Dated May8, 2018.


MADRIGAL PHARMACEUTICALS, INC. Exhibit
EX-99.1 2 a18-13013_1ex99d1.htm EX-99.1 Exhibit 99.1   Madrigal Pharmaceuticals Reports 2018 First Quarter Financial Results and Reviews Key Clinical Achievements   CONSHOHOCKEN,…
To view the full exhibit click here

About MADRIGAL PHARMACEUTICALS,INC. (NASDAQ:MDGL)

Madrigal Pharmaceuticals, Inc., formerly Synta Pharmaceuticals Corp., is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and nonalcoholic steatohepatitis (NASH). The Company’s lead product, MGL-3196, is a Phase II-ready once-daily, oral, liver-directed selective thyroid hormone receptor-b (THR-b) agonist for the treatment of NASH, and heterozygous and homozygous familial hypercholesterolemia (FH). Its product pipeline also includes MGL-3745, which is used in the treatment of NASH and FH. MGL-3196 has completed Phase I single and multiple dose trials in healthy volunteers. MGL-3196 is being developed for dyslipidemia/hypercholesterolemia to lower low-density lipoproteins cholesterol, triglyceride levels and lipoprotein(a). MGL-3196 also reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.